Investigation of the effects of sitagliptin, a DPP-4 inhibitor, on glycaemic control and renal markers in patients with type 2 diabetes mellitus.
Phase of Trial: Phase II
Latest Information Update: 29 Jul 2015
At a glance
- Drugs Sitagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics
- 29 Jul 2015 New trial record
- 09 Jun 2015 Results presented at the 75th Annual Scientific Sessions of the American Diabetes Association.